

Mukhopadhyay et al: AdV T cell cross-reactivity

1 **Title:** Adenovirus-specific T cells in adults are frequent, cross-reactive to common childhood  
2 adenovirus infections and boosted by adenovirus-vectored vaccines

3 Short title: AdV T cell cross-reactivity

4 **Authors**

5 Rookmini Mukhopadhyay<sup>1</sup>, Arnold W. Lambisia<sup>2</sup>, Jennifer P. Hoang<sup>1</sup>, Benjamin J. Ravenhill<sup>3</sup>, Charles  
6 N. Agoti<sup>2</sup>, Benjamin A.C. Krishna<sup>4</sup>, Charlotte J. Houldcroft<sup>1\*</sup>

7 \*Corresponding author: CJH [ch504@cam.ac.uk](mailto:ch504@cam.ac.uk)

8 **Affiliations**

- 9 1. Department of Genetics, University of Cambridge, Cambridge, CB2 3EH, United Kingdom
- 10 2. Kenya Medical Research Institute-Wellcome Trust Research Programme, PO Box 230-80108,  
11 Kilifi, Kenya
- 12 3. Cambridge Institute for Medical Research, School of Clinical Medicine, University of  
13 Cambridge, Cambridge, CB2 0XY, United Kingdom
- 14 4. Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, United Kingdom

15 **Abstract** (245/250)

16 Human adenoviruses (HAdVs) cause diverse disease presentations as pathogens, and are also used as  
17 viral vectors for vaccines and gene therapy products. Preexisting adaptive immune responses to  
18 HAdV are known to influence symptom severity, viral clearance and the success of viral vectored  
19 products. Of note, approximately 50% of the UK's adult population has received at least one dose of  
20 a chimpanzee adenovirus vectored SARS-CoV-2 vaccine (ChAdOx1) since January 2021.

21 We used FluoroSpot analysis to quantify the interferon gamma (IFN $\gamma$ ) and interleukin-2 (IL2)  
22 responses of healthy blood donors to HAdV species A, B, C, D and F and chimpanzee adenovirus Y25,  
23 related to HAdV species E. We find that cellular immune responses to multiple species of human  
24 adenovirus are ubiquitous among healthy adult blood donors, and that stimulating PBMC with whole  
25 hexon peptide libraries induces a significantly greater IFN $\gamma$  and IL2 response than using selected  
26 peptide pools alone. We then compared the cellular immune responses of ChAdOx1 recipients and  
27 control donors using PBMC collected in 2021, and found that homotypic and heterotypic IFN $\gamma$   
28 responses were significantly boosted in ChAdOx1 recipients but not controls. Finally, we show that in  
29 PBMC derived from blood donors, IFN $\gamma$  responses are made to both conserved and variable regions  
30 of the hexon protein.

31 Future vaccination campaigns using adenoviral vectored vaccines will need to account for the pre-  
32 existing exposure of recipients to both circulating HAdVs and vaccines such as ChAdOx1, which  
33 convey polyfunctional antiviral T cell responses to even low seroprevalence HAdV types.

34 **Keywords**

35 Cellular immunity

36 Vaccination

37 Viral vectors

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Mukhopadhyay et al: AdV T cell cross-reactivity

38 DNA virus

39

40 **Abbreviations**

41 ChAd Chimpanzee adenovirus

42 ELISA Enzyme-linked immunosorbent assay

43 FluoroSpot Fluorescence-linked immunosorbent spot

44 HAdV Human adenovirus

45 HRA Health Research Authority

46 IFN $\gamma$  Interferon gamma

47 IL2 Interleukin 2

48 nAbs Neutralising antibodies

49 NHSBT National Health Service Blood & Transplant

50 PBMC Peripheral blood mononuclear cells

51 SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2

52 SFU Spot forming units

53

54 Introduction

55 Adenoviruses (AdVs) are non-enveloped, double-stranded DNA viruses with icosahedral capsids.  
56 Their capsids comprise three proteins: hexon, penton and fiber <sup>1</sup>. More than 100 human  
57 adenoviruses (HAdVs) have been identified to date, which have been classified into seven species (A  
58 to G). The majority of primary HAdV infections occur during the first five years of life, and cause  
59 symptoms ranging from upper and lower respiratory tract infections and keratoconjunctivitis, to  
60 gastro-intestinal disease and fulminant infection <sup>2</sup>. Currently there is no approved treatment for  
61 adenovirus infection, and no vaccine available for civilian use <sup>3,4</sup>. Different adenoviral species are  
62 associated with different kinds of disease, and recombination in the hexon, penton and fiber genes of  
63 a given adenovirus can alter its tissue tropism and resulting symptom profile <sup>5</sup>.

64 There has been significant interest in the immune response against HAdVs, largely driven by the  
65 problem of pre-existing HAdV immunity against HAdV-derived vectors, which suppresses the efficacy  
66 of immunisation <sup>6</sup>. This is likely due to a biasing of immune responses to memory responses against  
67 the AdV backbone rather than *de novo* responses to the vaccine antigen. Previous studies have  
68 primarily focused on HAdV-C5. Passive neutralising antibody (nAb) transfer experiments in naïve  
69 mice dampened immune stimulation by HAdV-C5 vectors, but to a lesser extent than the dampening  
70 observed in pre-immune mice. This demonstrates that nAbs alone cannot account for all pre-existing  
71 immunity, implicating AdV-specific T cells in the AdV-induced immune response <sup>7</sup>. Passive transfer of  
72 CD8<sup>+</sup> T cells into naïve mice significantly decreased the immune response induced by HAdV-C5  
73 vectors, highlighting their role in immune dampening <sup>7</sup>. The role of T cells in adenoviral clearance is  
74 further illustrated by the success of adoptive T-cell therapy, where HAdV-infected patients are  
75 treated by transfusion of HAdV-specific T cells, with an overall 75% response rate in 63 HAdV-positive  
76 HSCT patients across 10 clinical trials <sup>8</sup>. These data reinforce the importance of T cells in resolving  
77 HAdV infection in healthy and immunocompromised individuals and their potential role in  
78 dampening the immunisation efficacy of HAdV-derived vectors due to cross-reactivity.

79 Previous studies have suggested that HAdV-specific T cells are cross-reactive, capable of recognising  
80 a broad range of HAdVs. This is exemplified by the ability of HAdV-specific T cells to recognise  
81 chimpanzee-derived AdVs <sup>9</sup>. Cross-reactivity arises from the ability of T cells to recognise conserved  
82 peptide regions, usually in the hexon <sup>10</sup>. MHC-II-restricted CD4<sup>+</sup> epitopes have been identified  
83 throughout the hexon, but predominantly in the conserved regions <sup>9-11</sup>, while MHC-I-restricted CD8<sup>+</sup>  
84 T cell epitopes have also been identified mainly in the hexon, but also in the penton and fibre <sup>10,12,13</sup>.  
85 T cell responses to conserved regions are presumably recalled repeatedly upon infection with  
86 different HAdVs, whereas responses to variable regions are less frequently stimulated <sup>9</sup>. By contrast,  
87 nAbs show limited cross-neutralisation of different HAdV subtypes, which is a consequence of nAbs  
88 targeting peptide regions with high heterogeneity, such as the hexon hypervariable regions (HVRs) <sup>14-</sup>  
89 <sup>16</sup>.

90 In addition to the cellular immune landscape of natural HAdV infection, approximately 50% of the  
91 UK's adult population have received ChAdOx1, the Oxford-Astra Zeneca SARS-CoV-2 vaccine <sup>17</sup>. This is  
92 a viral-vectored vaccine which is based on chimpanzee adenovirus Y25 (GenBank accession:  
93 JN254802), and contains a deletion of Y25 genes E4, ORFs 4, 6, 7 and the 34K CDS region and  
94 insertion of the equivalent portion of the human adenovirus C5 genome <sup>18,19</sup>.

Mukhopadhyay et al: AdV T cell cross-reactivity

95 We therefore set out to investigate the interferon gamma (IFN $\gamma$ ) and interleukin 2 (IL2) T cell  
96 response of healthy blood donors to diverse human adenoviruses from multiple species; to establish  
97 whether the T cell response to a non-species C human adenovirus was confined to the conserved  
98 regions of the hexon protein; and to quantify what effect the use of ChAdOx1 has had on the  
99 landscape of anti-adenovirus T cell immunity in UK donors.

100

Mukhopadhyay et al: AdV T cell cross-reactivity

101 Methods

102 **Donors**

103 Healthy blood donors

104 Samples from ten anonymised healthy blood donors were collected from NHS Blood and Transplant  
105 (NHSBT), Cambridge Donor Centre. Ethical permission for “Understanding humoral and cellular  
106 immune responses to DNA viruses in healthy blood donors” was granted by the HRA and Health and  
107 Care Research Wales (HCRW) (REC reference 22/WA/0162). PBMC and serum were collected from  
108 leukocyte reduction system cones, a by-product of the platelet donation process. PBMC were  
109 separated from cones following a previously published protocol<sup>20</sup> using pluriSelect PBMC 24+ Spin  
110 Medium (Cambridge Bioscience, Cambridge, UK). Platelet donors from whom leukocyte cones were  
111 derived are aged between 17 and 70; specific age and sex data for individual donors was not  
112 available.

113 Twenty one donors of known SARS-CoV-2 vaccine status were recruited in 2021, all patients gave  
114 informed written consent in accordance with the Declaration of Helsinki. Ethical permission for the  
115 ARIA (Anti-viral Responses in Ageing, CBR53) study was granted by the Cambridge Human Biology  
116 Research Ethics Committee (HBREC.2014.07). Donors were grouped as recipients of one or more  
117 doses of ChAdOx1 vaccine (ChAdOx1 recipients), n = 11; or one or more doses of mRNA vaccine or  
118 no vaccine at the point of blood donation (controls), n = 10.

119 For both cohorts, PBMC were separated, frozen and thawed as previously described<sup>21</sup>. Cell viability  
120 was determined using trypan blue exclusion staining and counting of live cells using a  
121 haemocytometer.

122 **Serology**

123 In blood donors, IgG responses to HAdV-C5 were measured by ELISA using a Human Adenovirus IgG  
124 (ADV-IgG) ELISA Kit [AE24150HU] (Abebio, Wuhan, China), following the manufacturer’s  
125 recommended protocol. For samples 2301-2304, haemolysate was used to counter erythrocyte  
126 contamination due to NHSBT cone storage duration of longer than 12 hours before serum sampling;  
127 for samples 2305-2310, serum was used.

128 **Peptide stimulants**

129 Adenovirus ORF and other peptide mixes

130 Six commercially available, and two custom, peptide pools were selected to represent the diversity of  
131 human adenovirus species (**Table 1**). Commercial peptide pools from Miltenyi and JPT (Table 1) were  
132 diluted to a concentration of 5µg/ml/peptide. A custom library of consecutive 15-mer peptides  
133 overlapping by 5 amino acids were synthesised by GenScript (Oxford, UK) using the HAdV-A12 hexon  
134 sequence (GenBank accession: NP\_040924.1). Individual lyophilised peptides from each custom ORF  
135 library were reconstituted in 20% DMSO-80% RPMI-1640 (Sigma) at 10mg/ml master stock.  
136 Individual peptides were then diluted in RPMI-1640 to give a 1mg/ml (2% DMSO) working stock.  
137 Peptide pools were used as either entire ORF mixes at a concentration of 5µg/ml/peptide (final  
138 working concentration shown in Table 1) or formed into pools of 40-60 peptide pool of conserved  
139 and variable epitopes (see below), at a concentration of 20µg/ml/peptide.

140 **Table 1**

| Name   | Supplier  | Adenovirus species and type | Final concentration |
|--|-----------|-----------------------------|---------------------|
| Custom HAdV A12 hexon pool                                 | GenScript | A: 12                       | 2µg/ml/peptide      |
| HAdV-A conserved and variable pools                        | GenScript | A: 12                       | 20µg/ml/peptide     |
| PepMix HAdV-3 hexon (PM-HAdV3)                             | JPT       | B: 3                        | 2µg/ml/peptide      |
| PepTivator AdV Select (130-124-394)*                       | Miltenyi  | C: 2 and 5                  | 2µg/ml/peptide      |
| PepTivator AdV5 Hexon (130-093-495)                        | Miltenyi  | C: 5                        | 2µg/ml/peptide      |
| PepTivator AdV5 Penton (130-096-777)                       | Miltenyi  | C: 5                        | 2µg/ml/peptide      |
| PepMix Human Adenovirus 26 Hexon (PM-HADV26-L3-1)          | JPT       | D: 26                       | 2µg/ml/peptide      |
| PepMix Human Adenovirus 26 Penton (PM-HADV26-L2-1)         | JPT       | D: 26                       | 2µg/ml/peptide      |
| Custom HAdV F41 hexon pool                                 | GenScript | F: 41                       | 2µg/ml/peptide      |
| PepMix Chimpanzee Adenovirus Y25 Hexon (PM-CHADVY25-L3-1)  | JPT       | ChAd: Y25                   | 2µg/ml/peptide      |
| PepMix Chimpanzee Adenovirus Y25 Penton (PM-CHADVY25-L2-1) | JPT       | ChAd: Y25                   | 2µg/ml/peptide      |

141 \*AdV Select is a pool of 50 MHC class I and class II restricted oligopeptides derived from human  
 142 adenovirus species C genotypes 2 and 5.

143 Defining conserved versus variable regions

144 Peptides were defined as conserved if there were eight consecutive amino acids out of fifteen  
 145 identical between the C5 and A12 hexon amino acid reference sequences (AP\_000211.1 and  
 146 NP\_040924.1 respectively). The epitopes constituting the A12 conserved 1, conserved 2 and variable  
 147 pools are listed in **SUPPLEMENTARY TABLE 1**.

148 **Detection of Cytokine Production in PBMC by FluoroSpot**

149 PBMC were incubated in pre-coated human IFN $\gamma$  and IL2 FluoroSpot plates (Mabtech AB, Nacka  
 150 Strand, Sweden) in triplicate with ORF peptide pools (final peptide concentration shown in **TABLE 1**  
 151 following dilution with TexMacs) and an unstimulated and positive control mix [containing anti-CD3  
 152 and anti-CD28 (ImmunoCult Human CD3/CD28 T Cell Activator, StemCell)], for 48h at 37°C. Cells and  
 153 media were decanted from the plate and developed following the manufacturer's protocol. After  
 154 development and drying overnight, plates were read using an AID iSpot reader (Oxford Biosystems,  
 155 Oxford, UK) and spot-forming units were counted using AID EliSpot v7 software (Autoimmun  
 156 Diagnostika GmbH, Strasberg, Germany).

157 The mean spot forming units (SFU) were converted to SFU per 10<sup>6</sup> PBMC, the mean background  
 158 response (SFU/10<sup>6</sup> cells) was deducted from the mean of the corresponding wells. The cutoff for a  
 159 positive response was 50 SFU/10<sup>6</sup> cells for IFN $\gamma$  responses and 10 SFU/10<sup>6</sup> for IL2 responses, defined  
 160 based on responses to SARS-CoV-2 and adenovirus vectored vaccines as no clinical T cell correlate of  
 161 protection is currently defined for human adenoviruses<sup>22-24</sup>. Values at or below zero were plotted as  
 162 0.1 to allow their visualisation on logarithmic axes.

Mukhopadhyay et al: AdV T cell cross-reactivity

163 Donors were excluded from further analysis if they failed to produce above-background IFN $\gamma$   
164 responses to positive control stimulation, compared to the negative control.

### 165 **Multiple sequence alignment and amino acid distance calculations**

166 Hexon amino acid sequences for HAdVs A12 (NP\_040924.1), C5 (AP\_000211.1), B3  
167 (YP\_002213779.1), D26 (ABO61316.1), F41 (ACH90432.1) and ChAd Y25 (YP\_006272963.1) were  
168 retrieved from GenBank. Sequences were aligned in MEGA11 using MUSCLE and manually inspected.  
169 Estimated evolutionary distances between amino acid sequences were calculated in MEGA11 as the  
170 number of amino acid substitutions per site between sequences, with a Poisson correction model.  
171 Ambiguous positions were removed for each sequence pair using the pairwise deletion option. There  
172 were 976 positions in the final dataset.

### 173 **Statistical analyses**


174 Data were tested for normality using Shapiro–Wilk tests and parametric or non-parametric statistical  
175 tests chosen accordingly. Spearman’s R was calculated for the averaged background corrected SFU  
176 per 10<sup>6</sup> PBMC for each pair of hexon proteins. SFU which were 0 after background correction are  
177 represented as 0.1 on log scale graphs. Unless otherwise stated, statistical analysis and graphing  
178 were performed in GraphPad Prism v10.2. A Mantel test of the relationship between hexon pairwise  
179 amino acid distances and IFN $\gamma$  response correlations was performed in Matlab 2021b, using the  
180 Fathom toolbox (Jones, 2017), set at 9999 permutations.

## 181 Results

### 182 **Serological responses to adenovirus C5 are relatively uncommon**

183 Serum antibody responses to adenovirus are often used as proxy for previous infection history <sup>26</sup> .  
184 We therefore measured anti-adenovirus C5-IgG levels by ELISA in each of our healthy donors. 2/10  
185 donors had a positive IgG response to adenovirus C5, and 4/10 had equivocal responses (confidence  
186 intervals overlapping the cutoff). The remaining four donors were seronegative. This is broadly in line  
187 with binding antibody data collected in Germany <sup>27,28</sup>, where binding antibody levels were higher for  
188 genotype C1 than C5, and for previous serology surveys conducted in Europe <sup>26</sup>. This may also mirror  
189 the significant post-COVID reduction in binding antibody levels seen in German healthy serum donors  
190 between 2019 and 2021 <sup>28</sup>, but the numbers presented here are small. No comparable data is  
191 available for England.

### 192 **FIGURE 1**



193

194 **Figure 1 legend:** Plot showing serum antibody responses to adenovirus C5 in healthy blood donors.  
195 Optical density measurements were made using an ELISA specific for HAdV C5 and were background-  
196 corrected.

197 **Interferon gamma-producing responses to adenoviruses are pervasive and IL2 responses are seen**  
198 **in the majority of healthy donors**

199 IFN $\gamma$  responses, measured by FluoroSpot or similar technologies, are an *in vitro* proxy for *in vivo*  
200 antiviral T cell recognition and response to viral peptides. T cell responses are an alternative tool for  
201 identifying previous viral pathogen exposure in seronegative individuals<sup>22</sup>. Using peptides derived  
202 from prevalent adenovirus species C genotypes, we found that 7/10 donors made a positive IFN $\gamma$   
203 response to the AdV Select (C2 and C5) pool, and 8/10 to the C5 hexon peptide pool. The AdV Select  
204 pool is a set of peptides spanning epitopes experimentally identified from genotypes 2 and 5, while  
205 the C5 hexon pool tiles the whole of the immunodominant hexon protein. All donors made a positive  
206 IFN $\gamma$  response to the hexons of HAdVs-A12, B3, and D26, demonstrating clear exposure to a range of  
207 HAdV species even in the absence of detectable antibody serology.

208 IL2 responses are a proxy for CD4<sup>+</sup> T cell recognition of viral peptides<sup>29</sup>. Similar to IFN $\gamma$ , 7/10 donors  
209 had a positive IL2 response to the C5 hexon pool and 3/10 donors had a positive response to the C5  
210 penton pool. However, fewer donors made a positive response IL2 (4/10 donors) to the AdV Select  
211 pool, compared to IFN $\gamma$  (7/10).


212

213 **Figure 2**




**A**

### Total PBMC IFN $\gamma$ responses to adenovirus peptide stimulation



**B**

### Total PBMC IL-2 responses to adenovirus peptide stimulation



214

215

Mukhopadhyay et al: AdV T cell cross-reactivity

216 **Figure 2 legend:** Analysis of AdV specific IFN $\gamma$  and IL2 FluoroSpot responses to AdV peptide pools (A)  
217 IFN $\gamma$  FluoroSpot responses to AdV peptide pools covering: an experimentally-validated set of 50 AdV  
218 C2 and 5 peptides (AdSelect), peptide pools covering the entire hexons of human adenoviruses A12,  
219 B3, C5, D26, F41 and the hexon of chimpanzee adenovirus Y25 (vector backbone of SARS-CoV-2  
220 vaccine ChAdOx1), as well as a polyclonal anti-CD3/CD28 antibody T cell stimulation as a positive  
221 control of PBMC from healthy blood donors, calculated as spot-forming units (SFU) per 10e6 PBMC  
222 (background corrected). (B) IL2 FluoroSpot responses to AdV peptide pools covering: an  
223 experimentally-validated set of 50 AdV C2 and 5 peptides (AdSelect), pools covering the entire  
224 hexons of human adenoviruses A12, B3, C5, D26, F41, the hexon of chimpanzee adenovirus Y25  
225 (vector backbone of SARS-CoV-2 vaccine ChAdOx1), as well as a polyclonal anti-CD3/CD28 antibody T  
226 cell stimulation as a positive control of PBMC from healthy blood donors, calculated as spot-forming  
227 units (SFU) per 10e6 PBMC (background corrected). Significance determined by two-way ANOVA,  
228 corrected for multiple testing. Key: \* $p < 0.05$ . The dotted lines indicate the boundary between a  
229 positive and a negative response.

230


231 **Interferon gamma and interleukin-2 responses to adenovirus penton peptide pools are less**  
232 **common in healthy blood donors than hexon responses**

233 The adenovirus penton protein is a known to be a target of human T cell responses, though the  
234 relative contribution of the penton and hexon to the T cell response to adenovirus infection is  
235 currently an area of active research<sup>30</sup>. We therefore quantified the IFN $\gamma$  and IL2 responses to two  
236 commercially available human adenovirus penton peptide pools: HAdVs-C5 and D26.

237 We found that positive IFN $\gamma$  responses to the C5 penton were less common than C5 hexon  
238 responses, with 3/10 donors responding to the C5 penton peptide pool (**Figure 3**) compared to 8/10  
239 responding to the hexon pool (**Figure 2**). The same was also true of D26 (5/10 responding to the  
240 penton, compared to 10/10 responding to the hexon).

241 Similar trends were seen for IL2 responses, with 2/10 donors responding to penton peptide pools  
242 derived from C5, and 6/10 responding to D25 (**Figure 3**).

243 **FIGURE 3**



244

245 **Figure 3 legend:** Analysis of AdV specific IFN $\gamma$  and IL2 FluoroSpot responses to AdV peptide pools (A)  
246 IFN $\gamma$  FluoroSpot responses to AdV peptide pools covering: the pentons of human adenoviruses C5  
247 and D26, and the penton of chimpanzee adenovirus Y25 (vector backbone ChAdOx1) as well as a  
248 polyclonal anti-CD3/CD28 antibody T cell stimulation as a positive control of PBMC from healthy  
249 blood donors, calculated as spot-forming units (SFU) per 10e6 PBMC (background corrected). (B) IL2  
250 FluoroSpot responses to AdV peptide pools covering: the pentons of human adenoviruses C5 and  
251 D26, and the penton of chimpanzee adenovirus Y25 (vector backbone ChAdOx1) as well as a  
252 polyclonal anti-CD3/CD28 antibody T cell stimulation as a positive control of PBMC from healthy  
253 blood donors, calculated as spot-forming units (SFU) per 10<sup>6</sup> PBMC (background corrected).

254

255 **IFN $\gamma$  and IL2 responses to the hexon of the ChAdOx1 vector, chimpanzee adenovirus Y25, are**  
256 **ubiquitous among healthy blood donors recruited in 2023.**

257 In 2021-2022, an estimated 50% of the UK's adult population received at least one dose of an  
258 adenovirus-vectored SARS-CoV-2 vaccine, predominantly ChAdOx1<sup>17</sup>. The ChAdOx1 vector is based  
259 on ChAd-Y25, retaining the ChAd-Y25 hexon and penton<sup>18,19</sup>. ChAd-Y25 has homology to HAdV  
260 species E<sup>19</sup>, which is associated with outbreaks of respiratory disease in congregate settings<sup>31</sup>.

261 We found that 10/10 healthy blood donors made a positive IFN $\gamma$  response to the hexon of ChAd-Y25  
262 (ChAdOx1) and 9/10 donors made a positive IL2 response (**Figure 2**). Similar to observations of  
263 human adenovirus-derived penton peptide pools, fewer healthy donors made a positive IFN $\gamma$  (7/10)  
264 or IL2 (5/10) response to the ChAdOx1 penton (**Figure 3**) than the hexon.

Mukhopadhyay et al: AdV T cell cross-reactivity

265 **Positive IFN $\gamma$  responses to ChAdOx1 and C5 hexon peptide pools are more common in ChAdOx1**  
266 **vaccine recipients than controls**

267 Among anonymised apheresis cones from healthy blood donors recruited in 2023, ChAdOx1  
268 vaccination status was not available. We hypothesised that among healthy donors of known  
269 ChAdOx1 recipient status, ChAdOx1 recipients would have higher T cell responses to the ChAdOx1  
270 vector hexon than recipients who had received an mRNA SARS-CoV-2 vaccine or no vaccine instead.  
271 We also hypothesised that boosting of C5 hexon T cell responses might occur due to vaccine-induced  
272 activation of cross-reactive T cells which recognised shared epitopes. We therefore compared PBMC  
273 responses to the ChAdOx1 and C5 hexons in healthy controls and ChAdOx1 recipients of known  
274 vaccine status, vaccinated and recruited in 2021.

275 Positive IFN $\gamma$  responses to ChAdOx1 and C5 hexon peptide pools, defined as >50 SFU/10e6 cells,  
276 were more common among ChAdOx1 SARS-CoV-2 vaccine recipients than controls (mRNA SARS-CoV-  
277 2 vaccine or no vaccine). 7/10 ChAdOx1 recipients had a positive IFN $\gamma$  response to the ChAdOx1  
278 hexon peptide pool while 2/11 controls had a positive response to Y25. 5/10 ChAdOx1 recipients had  
279 a positive IFN $\gamma$  response and 1/11 controls had a positive IFN $\gamma$  response to the C5 peptide pool. We  
280 found that IFN $\gamma$  T cell responses were statistically significantly higher in ChAdOx1 recipients for both  
281 their responses to the Y25 (ChAdOx1) hexon (mean SFU/10e6 cells 143.1, SD 169.1 vs mean  
282 SFU/10e6 cells 79.6, SD 203.7; Mann Whitney U test (two-tailed)  $p = 0.023$ ) and the C5 hexon (mean  
283 SFU/10e6 cells 66.01, SD 49.45 vs mean SFU/10e6 cells 18.8, SD 48.5; Mann Whitney U test (two  
284 tailed)  $p = 0.005$ ) peptide pools.


285 IL2 responses were similar between ChAdOx1 recipients and controls. 5/10 ChAdOx1 recipients had a  
286 positive IL2 response to the Y25 (ChAdOx1) hexon peptide pool, defined as >10 SFU/10e6 cells, while  
287 1/11 controls had a positive response. 4/10 ChAdOx1 recipients and 2/11 controls had a positive IL2  
288 response to the C5 hexon peptide pool. The differences in mean SFU between the two groups were  
289 not statistically significant (Mann Whitney U test (two tailed), Y25  $p = 0.19$ ; C5  $p = 0.34$ ).

290 There was a statistically significant correlation in the frequency of IFN $\gamma$  T cell responses to Y25 and C5  
291 in the 2021 vaccine recipients ( $r^2 = 0.87$ ,  $p = <0.0001$ ) (**supplementary figure 1**). This appears to be  
292 driven largely by the ChAdOx1 recipients ( $r^2 = 0.82$ ,  $p = 0.0001$ ), as the correlation was not  
293 statistically significant in the controls ( $R^2 = 0.03$ ,  $p = 0.6$ ). There was no statistically significant  
294 correlation between the frequency of IL2 T cell responses to Y25 and C5 in the 2021 vaccine  
295 recipients ( $r^2 = 0.06$ ,  $p = 0.42$ ; data not shown) or any subgroup.

296

297 **FIGURE 4**

298



299

300 **Figure 4 legend:** Frequency of IFN $\gamma$  and IL2 responses to adenovirus peptide pools covering the  
301 hexon proteins of Y25 and C5 in ChAdOx1 vaccine recipients and controls, expressed as spot-forming  
302 units per 10e6 PBMC (background corrected). P values were calculated with a Mann-Whitney U test.

### 303 Relationship between the frequency of cytokine responses between species

304 Adenovirus-specific T cell responses have previously been reported to be cross-reactive within and  
305 between adenovirus species<sup>9,32</sup>. Therefore, we hypothesised that cross-reactive T cells from the  
306 same donor should recognise peptides from multiple different adenovirus species, and that the


Mukhopadhyay et al: AdV T cell cross-reactivity

307 magnitude of the response should be positively correlated: i.e. the IFN $\gamma$  and IL2 response should be  
308 produced by a mixture of type or species-specific T cells, and also a population of cross-reactive T  
309 cells. Previous research suggests that the proportion of cross-reactive T cells should be higher than  
310 the proportion of type/species-specific T cells.

311 We investigated this by calculating the correlations in the magnitude of SFU responses between each  
312 pair of hexon sequences. A number of pairs of hexon sequences had statistically significant  
313 Spearman's  $r$  coefficients for the frequency of IFN $\gamma$  responses (**FIGURE 5**). There was a statistically  
314 significant relationship between the IFN $\gamma$  and IL2 responses for genotypes A12 and ChAdOx1 (Y25),  
315 B3 and D26, B3 and F41, and D26 and F41. IL2 response correlations are shown in **supplementary**  
316 **figure 2**. Correlations between C5 and D26 and C5 and F41 were only significant for IFN $\gamma$  responses.

317 Not all pairs of hexons had significantly correlated IFN $\gamma$  and/or IL2 response frequencies. This  
318 suggests that cross-reactivity of adenovirus-specific T cell responses may not apply equally across  
319 adenovirus species. Furthermore, a Mantel test of the correlation between genetic distances of  
320 paired hexon amino acid sequences, and the correlations in IFN $\gamma$  responses between pairs of hexons,  
321 was not statistically significant. This suggests that shared infection history may explain the  
322 correlations between hexon pairs, rather than the degree of amino acid conservation.

323 **FIGURE 5**



324


325 Figure 5 legend: Plots showing the correlation between the frequency of IFN $\gamma$  responses for pairs of  
326 hexons for ten healthy donors. Each axis shows the number of SFUs per 10<sup>6</sup> PBMC produced by each  
327 donor in response to hexon peptide pool stimulation. Spearman's  $r$  correlation coefficients and two-  
328 tailed  $p$  values shown for statistically significant correlations.

329 **Many donors make IFN $\gamma$  T cell responses to variable regions of the hexon**

330 In adenovirus C, previous work had identified conserved regions of the hexon protein to be  
331 important for the T cell response, and in particular the CD4<sup>+</sup> T cell response (eg<sup>33</sup>). In order to  
332 understand the relative contribution of variable and conserved regions of the hexon to the T cell  
333 response to adenovirus, the adenovirus A12 hexon was divided into three pools: one containing  
334 variable epitopes which are not highly conserved between adenovirus species, and two conserved  
335 pools, a 5' conserved pool 1 and a 3' conserved pool 2 (**supplementary table 1**) (**Figure 6A**). The  
336 variable pool included peptides which showed variation within species A genotypes. In a post-SARS-  
337 CoV-2 emergence sample of donor serum from Germany, binding antibody responses to A12 were  
338 higher on average than responses to other species A genotypes, suggesting A12 was a suitable and  
339 seroprevalent representative of adaptive immune responses to species A adenoviruses in a post-  
340 pandemic population<sup>27</sup>.


341 We found the cellular immune response to A12 to include detectable IFN $\gamma$  responses to all regions of  
342 the protein, while the IL2 responses was more variable from donor to donor. 5/6 healthy blood  
343 donors made an IFN $\gamma$  response to the variable portion of the hexon, while all donors made an IFN $\gamma$   
344 response to the 5' and 3' conserved regions. The IL2 response to the variable domain was absent in  
345 4/6 donors, in contrast to the IFN $\gamma$  response. 5/6 donors made an IL2 response to 5' conserved pool  
346 1, and 3/6 made responses to 3' conserved pool 2. This may reflect a bias of CD4<sup>+</sup> T cell responses  
347 towards the more conserved regions of the hexon protein, which is less marked for CD8<sup>+</sup> T cells.

348 **FIGURE 6**



349





350

351 **Figure 6 legend:** A: Diagram showing the location of the adenovirus A12 hexon in genomic context,  
352 and the composition of the conserved and variable peptide pools derived from this protein. B:  
353 Frequency of PBMC IFN $\gamma$  responses to the HAdV-A12 hexon, divided into two conserved and one  
354 variable epitope pool. Points show the mean (n=3) and SEM for each donor and pool. The dotted line  
355 indicates a positive IFN $\gamma$  response was defined as greater than 50 SFU/10<sup>6</sup> PBMC (background  
356 corrected). C: Frequency of PBMC IL2 responses to the conserved and variable epitope pools. The  
357 dotted line indicates a positive IL2 response was defined as greater than 10 SFU/10<sup>6</sup> PBMC  
358 (background corrected).

359

360



361 Discussion

362 The *de novo* T cell response to adenovirus infection is widely recognised as ameliorating the severity  
363 of disease<sup>34</sup>, while also playing a role in the success of adenovirus-vectored vaccines and gene  
364 therapy products<sup>35</sup>. In this study, we investigated the frequency and function of adenovirus-specific  
365 T cell responses in healthy donors using highly sensitive FluoroSpot assays, comparing responses to  
366 adenovirus proteins derived from five human and one chimpanzee adenovirus species. We also  
367 compared the effect of an adenovirus-vectored vaccine (ChAdOx1) on T cell responses to the vector  
368 (ChAdV-Y25) and a commonly used human adenovirus vector (HAdV-C5).

369 We note a significant dichotomy between the high frequency of T cell responses to different  
370 adenovirus species (Figure 2), and the relatively small frequency of donors with detectable binding  
371 antibody levels to HAdV-C5 (Figure 1). Recent data from healthy donors in Germany<sup>27,28</sup> suggests  
372 that this may be because that the majority of donors have low-level circulating binding antibody  
373 responses to C5, represented by low OD values. We speculate that ELISA-based serological analysis of  
374 adenovirus binding antibody responses may not be sufficiently sensitive to establish past adenovirus  
375 infection history and immunity on a per-genotype level. As with SARS-CoV-2, seroreversion may be a  
376 feature of infrequent adenovirus re-exposure and/or reinfection in the adult population<sup>22</sup>.  
377 Additionally, the “hit and run” strategy seen in these respiratory viruses may lead to low levels of  
378 serum antibodies in favour of mucosal responses dominated by IgA.

379 The commercial Peptivator AdV Select pool of peptides (Miltenyi) has been used for the generation  
380 of therapeutic anti-HAdV T cell products by a number of groups eg<sup>36,37</sup>, and consists of a defined,  
381 experimentally-validated set of HLA class I and II epitopes from HAdVs C2 and C5. We note that  
382 among healthy blood donors, more individuals made a detectable IL2 response to the HAdV C5  
383 hexon pool than the AdV Select pool. The HAdV5 hexon peptide pool tiles the entire protein, and  
384 thus is agnostic to the HLA type of the donor. Indeed, both IFN $\gamma$  and IL2 responses were statistically  
385 significantly more frequent to a peptide pool derived from the hexon of common respiratory HAdV  
386 B3 than to the AdV Select pool (**Figure 2**). This suggests that in donors of unknown HLA type, using a  
387 HAdV hexon pool which tiles the entire protein leads to more donors having a detectable IFN $\gamma$  and  
388 IL2 T cell response than the AdV Select pool alone when generating therapeutic T cells for AdV  
389 cellular therapy.

390 25 million first doses of the ChAdOx1 adenovirus-vectored SARS-CoV-2 vaccine were administered to  
391 the UK’s adult population received between 2021 and 2023<sup>17</sup>. Y25 is the vector backbone from  
392 which ChAdOx1 was derived. In 2012, neutralising antibody responses to the vector were reported to  
393 be low in the UK population, with no donors having neutralising antibody titres where ND50 is at  
394 serum dilutions over 200<sup>19</sup>; after immunisation with one or more doses of ChAdOx1, anti-vector IgG  
395 responses became detectable<sup>38</sup>. Other studies have also identified that use of a HAdV-C5 vectored  
396 COVID vaccine boosts neutralising antibody responses in seronegative recipients<sup>39</sup>. To the best of our  
397 knowledge, this is the first study to explore the degree of anti-vector T cell responses to Y25 since  
398 the UK’s ChAdOx1 vaccination campaign. Among platelet donors at NHSBT Cambridge, from whom  
399 leukocyte reduction cones are derived, T cell responses to Y25 viral surface proteins are now  
400 ubiquitous and of comparable magnitude to common genotypes such as C5. In samples collected in  
401 2021 from healthy donors, ChAdOx1 vaccine recipients had statistically significantly higher IFN $\gamma$   
402 responses to both Y25 and C5 hexons than controls, suggesting both a type-specific and cross-species  
403 boosting of cellular immunity to adenoviruses (**Figure 4, supplementary figure 1**). This may have

## Mukhopadhyay et al: AdV T cell cross-reactivity

404 important consequences for future vaccination campaigns or gene-therapy products wishing to use  
405 adenovirus vectors in individuals who have also received ChAdOx1.

406 Previous studies have shown that the hexon T cell response is equally distributed against both the  
407 variable and conserved regions of the protein<sup>9</sup> while others have suggested it is focused on  
408 conserved epitopes<sup>10,33</sup>. Our data suggest that IFN $\gamma$  responses, a proxy for CD8<sup>+</sup> T cell responses<sup>29</sup>,  
409 may be more skewed towards variable regions than previously thought (**Figure 6B**). The weak or  
410 absent correlation in the frequency of T cell responses to some pairs of hexons of different  
411 adenovirus species, and the common recognition of variable epitopes within the A12 hexon peptide  
412 pool by healthy blood donor PBMC, suggests an important species- or genotype-specific component  
413 of the IFN $\gamma$  response to adenovirus, which is therefore unlikely to be to conserved epitopes. There  
414 was no statistically significant correlation between amino acid distance between hexon pairs and the  
415 correlation in response frequency within donors, which suggests that shared infection history may  
416 explain the correlations in IFN $\gamma$  responses to the genotypes of some hexon pairs. In contrast, IL2  
417 responses (a proxy for the CD4<sup>+</sup> T cell response<sup>40</sup>) to the variable domain of the A12 hexon peptide  
418 pool were relatively unusual (2/6 donors), which supports previous studies on the CD4<sup>+</sup> T cell  
419 response being focused towards conserved epitopes (**Figure 6C**). The relative contribution of  
420 different classes of T cell response to adenovirus infection in adults merits further research in order  
421 to refine future vaccination and cellular therapy efforts.

### 422 **Conclusions**

423 We find that adenovirus-specific cellular immune responses to five HAdV species are widespread in  
424 UK blood donors, and include inflammatory cytokine responses to a widely-deployed SARS-CoV-2  
425 vaccine vector backbone (ChAd-Y25, used in the development of the ChAdOx1 vaccine). Responses  
426 to the penton protein are less commonly detected, and at a lower frequency. We find that IFN $\gamma$   
427 responses to variable regions of the hexon protein may be more common than previously thought,  
428 particularly for genotype A12, while IL2 responses are often focused on conserved domains. We also  
429 present evidence that cross-type and type-specific IFN $\gamma$ , but not IL2, responses have been boosted in  
430 ChAdOx1 recipients, with unknown consequences for population-level immunity or future  
431 adenovirus evolution.

### 432 **Funding**

433 This work was funded by a Royal Society research grant to CJH [RGS\R2\222009] and a Cambridge-  
434 Africa ALBORADA Trust grant to CNA and CJH. BACK was supported by a Wellcome award  
435 (225023/Z/22/Z). This work was supported by the Department of Genetics, University of Cambridge.

### 436 **Acknowledgements**

437 The authors thank Eleanor Lim, Mark Wills and Marina Metaxaki for phlebotomy support and James  
438 V. Taylor for Matlab assistance. This research was supported by the Cambridge NIHR BRC Cell  
439 Phenotyping Hub.

### 440 **Author contributions**

441 CJH conceived and designed the study. CJH, BJR and CNA supervised the study. RM, AWL, JPH, BACK  
442 and CJH performed the experiments and analysed the data. JPH, CNA, BACK, and CJH wrote the  
443 manuscript. All authors commented on the manuscript and approved submission.

444 **References**

- 445 1 Benko M, Aoki K, Arnberg N, Davison AJ, Echavarria M, Hess M *et al.* ICTV Virus Taxonomy  
446 Profile: Adenoviridae 2022. *Journal of General Virology* 2022; **103**: 001721.
- 447 2 Lion T, Wold W. Adenoviruses. In: Damania B, Cohen J (eds). *Fields Virology: DNA Viruses*.  
448 Wolters Kluwer, 2021, pp 129–171.
- 449 3 Al-Heeti OM, Cathro HP, Ison MG. Adenovirus Infection and Transplantation. *Transplantation*  
450 2022; **106**: 920–927.
- 451 4 Gray GC, Erdman DD. Adenovirus Vaccines. In: *Plotkin's Vaccines*. Elsevier, 2018, pp 121-  
452 133.e8.
- 453 5 Walsh MP, Chintakuntlawar A, Robinson CM, Madisch I, Harrach B, Hudson NR *et al.* Evidence  
454 of Molecular Evolution Driven by Recombination Events Influencing Tropism in a Novel Human  
455 Adenovirus that Causes Epidemic Keratoconjunctivitis. *PLoS One* 2009; **4**: e5635.
- 456 6 Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, Del Rio C *et al.* Extended Follow-up  
457 Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect  
458 Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine  
459 (Step Study). *J Infect Dis* 2012; **206**: 258–266.
- 460 7 Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, Gorgone DA *et al.* Neutralizing  
461 Antibodies and CD8 + T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5  
462 Vaccine Vectors . *J Virol* 2004; **78**: 2666–2673.
- 463 8 Walti CS, Stuehler C, Palianina D, Khanna N. Immunocompromised host section: Adoptive T-  
464 cell therapy for dsDNA viruses in allogeneic hematopoietic cell transplant recipients. *Curr*  
465 *Opin Infect Dis* 2022; **35**: 302–311.
- 466 9 Hutnick NA, Carnathan D, Demers K, Makedonas G, Ertl HCJ, Betts MR. Adenovirus-specific  
467 human T cells are pervasive, polyfunctional, and cross-reactive. *Vaccine* 2010; **28**: 1932–1941.
- 468 10 Leen AM, Sili U, Vanin EF, Jewell AM, Xie W, Vignali D *et al.* Conserved CTL epitopes on the  
469 adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells.  
470 *Blood* 2004; **104**: 2432–2440.
- 471 11 Veltrop-Duits LA, Heemskerk B, Sombroek CC, van Vreeswijk T, Gubbels S, Toes REM *et al.*  
472 Human CD4+ T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells  
473 infected with different species of human adenovirus. *Eur J Immunol* 2006; **36**: 2410–2423.
- 474 12 Leen AM, Christin A, Khalil M, Weiss H, Gee AP, Brenner MK *et al.* Identification of Hexon-  
475 Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy. *J Virol* 2008; **82**: 546–  
476 554.
- 477 13 Tang J, Olive M, Pulmanusahakul R, Schnell M, Flomenberg N, Eisenlohr L *et al.* Human CD8+  
478 cytotoxic T cell responses to adenovirus capsid proteins. *Virology* 2006; **350**: 312–322.
- 479 14 Toogood CIA, Crompton J, Hay RT. Antipeptide antisera define neutralizing epitopes on the  
480 adenovirus hexon. *Journal of General Virology* 1992; **73**: 1429–1435.
- 481 15 Pichla-Gollon SL, Drinker M, Zhou X, Xue F, Rux JJ, Gao G-P *et al.* Structure-Based Identification  
482 of a Major Neutralizing Site in an Adenovirus Hexon. *J Virol* 2007; **81**: 1680–1689.

Mukhopadhyay et al: AdV T cell cross-reactivity

- 483 16 Roberts DM, Nanda A, Havenga MJE, Abbink P, Lynch DM, Ewald BA *et al.* Hexon-chimaeric  
484 adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. *Nature* 2006  
485 441:7090 2006; **441**: 239–243.
- 486 17 MHRA FOI Team. AstraZeneca COVID-19 vaccination first doses given FOI 22/1217. 2023.
- 487 18 Radukic MT, To Le D, Müller KM. Nucleic Acid Sequence Composition of the Oxford –  
488 AstraZeneca Vaccine ChAdOx1 nCoV-19 (AZD1222, Vaxzevria). 2021. doi:10.21203/RS.3.RS-  
489 799338/V1.
- 490 19 Dicks MDJ, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC *et al.* A Novel Chimpanzee  
491 Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation  
492 and Comparative Immunogenicity. *PLoS One* 2012; **7**: e40385.
- 493 20 Poole E, Groves I, Jackson S, Wills M, Sinclair J. Using Primary Human Cells to Analyze Human  
494 Cytomegalovirus Biology. *Methods Mol Biol* 2021; **2244**: 51–81.
- 495 21 Houldcroft CJ, Jackson SE, Lim EY, Sedikides GX, Davies EL, Atkinson C *et al.* Assessing Anti-  
496 HCMV Cell Mediated Immune Responses in Transplant Recipients and Healthy Controls Using  
497 a Novel Functional Assay. *Front Cell Infect Microbiol* 2020; **10**: 275.
- 498 22 Krishna BA, Lim EY, Mactavous L, Lyons PA, Doffinger R, Bradley JR *et al.* Evidence of previous  
499 SARS-CoV-2 infection in seronegative patients with long COVID. *EBioMedicine* 2022; **81**.  
500 doi:10.1016/J.EBIOM.2022.104129.
- 501 23 Koukoulis K, Papayanni PG, Jones J, Kuvalekar M, Watanabe A, Velazquez Y *et al.* Assessment  
502 of the cytolytic potential of a multivirus-targeted T cell therapy using a vital dye-based, flow  
503 cytometric assay. *Front Immunol* 2023; **14**: 1299512.
- 504 24 Barnes E, Folgari A, Capone S, Swadling L, Aston S, Kurioka A *et al.* Novel adenovirus-based  
505 vaccines induce broad and sustained T cell responses to HCV in man. *Sci Transl Med* 2012; **4**.  
506 doi:10.1126/SCITRANSLMED.3003155/SUPPL\_FILE/4-115RA1\_SM.PDF.
- 507 25 Jones DL. Fathom Toolbox for Matlab | USF College of Marine Science.  
508 2017.[https://www.usf.edu/marine-science/research/matlab-resources/fathom-toolbox-for-](https://www.usf.edu/marine-science/research/matlab-resources/fathom-toolbox-for-matlab.aspx)  
509 [matlab.aspx](https://www.usf.edu/marine-science/research/matlab-resources/fathom-toolbox-for-matlab.aspx) (accessed 15 Apr2024).
- 510 26 Mennechet FJD, Paris O, Ouoba AR, Salazar Arenas S, Sirima SB, Takoudjou Dzomo GR *et al.* A  
511 review of 65 years of human adenovirus seroprevalence. *Expert Rev Vaccines* 2019; **18**: 597–  
512 613.
- 513 27 Klann PJ, Wang X, Elfert A, Zhang W, Köhler C, Güttsches AK *et al.* Seroprevalence of Binding  
514 and Neutralizing Antibodies against 39 Human Adenovirus Types in Patients with  
515 Neuromuscular Disorders. *Viruses* 2023; **15**: 79.
- 516 28 Wang X, Kerkmann L, Hetzel M, Windmann S, Trilling M, Zhang W *et al.* Analysis of the  
517 Prevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in  
518 Student Cohorts Reveals Low-Prevalence Types and a Decline in Binding Antibody Levels  
519 during the SARS-CoV-2 Pandemic. *J Virol* 2022; **96**. doi:10.1128/JVI.01133-  
520 22/ASSET/690BA172-2893-41C1-A330-92BF27AE837F/ASSETS/IMAGES/LARGE/JVI.01133-22-  
521 F006.JPG.
- 522 29 Slifka MK, Whitton JL. Antigen-Specific Regulation of T Cell–Mediated Cytokine Production.  
523 *Immunity* 2000; **12**: 451–457.

Mukhopadhyay et al: AdV T cell cross-reactivity

- 524 30 Tischer S, Geyeregger R, Kwoczek J, Heim A, Figueiredo C, Blasczyk R *et al.* Discovery of  
525 immunodominant T-cell epitopes reveals penton protein as a second immunodominant target  
526 in human adenovirus infection. *J Transl Med* 2016; **14**: 1–16.
- 527 31 Tori ME, Chontos-Komorowski J, Stacy J, Lamson DM, George KS, Lail AT *et al.* Identification of  
528 Large Adenovirus Infection Outbreak at University by Multipathogen Testing, South Carolina,  
529 USA, 2022 - Volume 30, Number 2—February 2024 - Emerging Infectious Diseases journal -  
530 CDC. *Emerg Infect Dis* 2024; **30**: 358–362.
- 531 32 Smith CA, Woodruff LS, Rooney C, Kitchingman GR. Extensive Cross-Reactivity of Adenovirus-  
532 Specific Cytotoxic T Cells. <https://home.liebertpub.com/hum> 2008; **9**: 1419–1427.
- 533 33 Onion D, Crompton LJ, Milligan DW, Moss PAH, Lee SP, Mautner V. The CD4+ T-cell response to  
534 adenovirus is focused against conserved residues within the hexon protein. *Journal of General*  
535 *Virology* 2007; **88**: 2417–2425.
- 536 34 Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K *et al.* Safe adoptive  
537 transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection  
538 after allogeneic stem cell transplantation. *Br J Haematol* 2006; **134**: 64–76.
- 539 35 Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG *et al.* Human adenovirus-  
540 specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. *J Clin*  
541 *Invest* 2012; **122**: 359–367.
- 542 36 Becken BA, Lamson DM, Gonzalez G, Patel S, St George K, Kajon AE. A Fulminant Case of  
543 Adenovirus Genotype C108 Infection in a Pediatric Stem Cell Transplant Recipient with x-  
544 Linked Lymphoproliferative Syndrome Type 1. *Viruses* 2024, Vol 16, Page 137 2024; **16**: 137.
- 545 37 Al-Akioui Sanz K, Echecopar Parente C, Ferreras C, Menéndez Ribes M, Navarro A, Mestre C *et*  
546 *al.* Familial CD45RA– T cells to treat severe refractory infections in immunocompromised  
547 patients. *Front Med (Lausanne)* 2023; **10**: 1083215.
- 548 38 Cervantes-Torres J, Cabello-Gutiérrez C, Dolores ·, Ayón-Núñez A, Soldevila G, Olguin-Alor R *et*  
549 *al.* Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2  
550 protective immunity in mice. *Applied Microbiology and Biotechnology* 2024 108:1 2024; **108**:  
551 1–15.
- 552 39 Amosova IV, Timoshicheva TA, Kadyrova RA, Zabrodskaya YA, Vakin VS, Grudin MP *et al.* The  
553 investigation of the dynamics of changes in neutralizing antibody titers against type 5  
554 adenovirus in the context of vaccination against a new coronavirus infection. *Virology* 2024;  
555 **594**: 110051.
- 556 40 Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the  
557 immune system. *Nature Reviews Immunology* 2012 12:3 2012; **12**: 180–190.

558